-
<![CDATA[Meeting the Needs of Patients With HIV: Virologic Suppression and the Expanding Treatment Landscape]]>
02 Nov 2025 04:41 GMT
… disease progression to AIDS, transforming HIV from a fatal …
National HIV/AIDS Strategy 2024 Progress Report. HIV.gov. … hiv/genvoya/genvoya_pi.pdf
Juluca. Prescribing information. ViiV Healthcare … White House. National HIV/AIDS Strategy for the …
-
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
03 Nov 2025 21:49 GMT
… , Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai …
-
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
22 Oct 2025 12:29 GMT
… by GSK and Pfizer, with Shionogi joining as a shareholder in 2024, ViiV Healthcare … focuses on developing innovative treatments for HIV and AIDS. The … long-acting formulation of Apretude is manufactured at GSK …
-
GSK plc (NYSE:GSK) Q3 2025 Earnings Call Transcript
30 Oct 2025 12:40 GMT
… and the continued performance of ViiV, we are now increasing … higher NCIs relating to ViiV’s strong performance.
Turning … Plc (NYSE:GSK) Follow Glaxosmithkline Plc (NYSE:GSK) Receive real … our HIV business forward and growing strongly and helping GSK navigate …
-
Ending the HIV Epidemic: New advances bring hope to Victoria County
29 Oct 2025 18:13 GMT
… services to every HIV/AIDS positive patient here … at ViiV Healthcare, emphasizes that anyone sexually active can contract HIV, … epidemic.
"Everyone is HIV possible — understanding that … the virus.
Additionally, HIV can be transmitted through …
-
<![CDATA[Clinical Takeaways From ViiV’s PASO DOBLE and CLARITY Studies ]]>
29 Oct 2025 02:13 GMT
… HIV therapy as well as prevention,” he said.
References
1.ViiV Healthcare … HIV-1-with-significantly-less-weight-gain
2. ViiV Healthcare … . Press release. ViiV Healthcare. October 15, 2025 … gsk.com/en-gb/media/press-releases/viiv-healthcare …
-
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
17 Oct 2025 16:57 GMT
… GSK), Pfizer Inc (NYSE:PFE) and Shionogi Inc.
NICE has recommended ViiV Healthcare … Merck’s New HIV Treatment Works As … effective in reducing HIV risk, with 69% … HIV-negative adults and 86% of healthcare providers preferred cabotegravir over Sunlenca.
ViiV …
-
Campaign seeks to plug HIV care gap for UK women
28 Oct 2025 14:04 GMT
… between women and healthcare professionals about HIV, backed by ViiV Healthcare, is being extended … to HIV therapy specialist ViiV, which is majority owned by GSK with Pfizer and … has been announced shortly after ViiV's bimonthly PrEP injection …
-
Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment
20 Oct 2025 20:47 GMT
… The Global Fund to Fight AIDS, Tuberculosis and Malaria (the … GSK) and ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer … 70 million people from AIDS, TB and malaria since … and solidarity to end AIDS, TB and malaria, …
-
Are Europe’s Migrants Acquiring HIV After Arrival?
27 Oct 2025 12:16 GMT
… ‑year analysis at the European AIDS Clinical Society (EACS) 2025 Annual … decrease and stagnation in new HIV diagnoses, migrants remain disproportionately affected … honoraria for educational talks for ViiV Healthcare, Merck, and Gilead Sciences. Penot …
About
© 1995-2025